Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 3/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | LYN | P07948 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | FLT1 | P17948 | 2/20 | 0.34 |
| ▸ | FLT4 | P35916 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | BLK | P51451 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2864348 | 0.80 | NR4A2 (0.40) | KDM4ESTAT3HIF1AMAP2K4ALPL | |
| SCHEMBL27921480 | 0.74 | CYP4F2 (0.33) | KDM4EMAP2K4LCKFYNCSF1R | |
| SCHEMBL13132306 | 0.74 | MAP2K4 (0.43) | KDM4ESTAT3HIF1AMAP2K4ALPL | |
| SCHEMBL1135530 | 0.74 | KDM4E (0.48) | KDM4ESTAT3HIF1AFLT3NR4A2 | |
| SCHEMBL30424394 | 0.74 | KDM4E (0.48) | KDM4ESTAT3HIF1AFLT3NR4A2 | |
| SCHEMBL23856764 | 0.72 | CA1 (0.54) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL30047280 | 0.72 | CA1 (0.54) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL31159083 | 0.71 | CA12 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9941705 | 0.71 | KDM4E (0.41) | KDM4ESTAT3HIF1AMAP2K4NR4A2 | |
| SCHEMBL27604923 | 0.69 | CFD (0.36) | KDM4EMAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9174981-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2651939-B1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2651939-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274244-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2012082689-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274244-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | MUSK, FGFR1, FRK | KDM4E 1691/4885STAT3 174/4885HIF1A 1290/4885 |
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | MUSK, FGFR1, PDGFRA | KDM4E 1837/4885STAT3 163/4885HIF1A 1188/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | KDM4E 1420/4885STAT3 184/4885HIF1A 1013/4885 |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | MUSK, TYRO3, IRAK3 | KDM4E 1462/4885STAT3 267/4885HIF1A 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.